MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/inf.0000000000000967

Медицинская библиотека · The Pediatric infectious disease journal · 2016

Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.

Kim Dong Soo, Jang Gwang Cheon, Cha Sung-Ho, Choi Soo-Han, Kim Hwang Min, Kim Ji Hong, Kang Jin Han, Kim Jong-Hyun, Kim Ki Hwan, Bang Joon, Naimi Zulaikha, Bouckenooghe Alain, Bosch-Castells Valérie, Houillon Guy

Клиническое исследование III фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

This study evaluated the effect of a booster vaccination of a new, live attenuated, Japanese encephalitis chimeric vaccine (JE-CV). Previously this vaccine has been used as a booster 12 months after priming with an inactivated vaccine and at >24 months after priming with the same JE-CV. This study evaluates the immunogenicity and safety of the JE-CV given at 12-24 months after JE-CV priming.

METHODS

Phase III, open-label study in the Republic of Korea in which 119 children previously vaccinated with JE-CV at 12-24 months of age received a JE-CV booster at 12-24 months after primary vaccination. JE neutralizing antibody titers were measured using >50% plaque reduction neutralization test prebooster and 1 month postbooster vaccination. Seroprotection (SP) was defined as ≥10 (1/dil). Safety was assessed for 28 days postvaccination by parental reports. Serious adverse events were monitored for 6 months postvaccination.

RESULTS

Antibody persistence was high prebooster (SP rate 93.5%). There was a strong anamnestic response postbooster vaccination, with an SP rate of 100% and a >50-fold increase in geometric mean titer from the prebooster level. Both antibody persistence and the booster response were independent of whether the booster was given at 12-17 or 18-24 months. The safety profile was good and comparable with the primary vaccination; there were no vaccine-related serious adverse events and no deaths.

CONCLUSIONS

This study confirms the suitability of a JE-CV booster vaccination at 12-24 months after a primary dose of the same vaccine given at 12-24 months of age in children in the Republic of Korea.

Для цитирования: Kim Dong Soo, Jang Gwang Cheon, Cha Sung-Ho, Choi Soo-Han, Kim Hwang Min, Kim Ji Hong, Kang Jin Han, Kim Jong-Hyun, Kim Ki Hwan, Bang Joon, Naimi Zulaikha, Bouckenooghe Alain, Bosch-Castells Valérie, Houillon Guy. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.. The Pediatric infectious disease journal. 2016. DOI: 10.1097/inf.0000000000000967.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.